WinstonA, PozniakA, SmithN, FletcherC, MandaliaS, ParmarD, et al.: Dose escalation or immediate full dose when switching from EFV to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?. AIDS, 2004; 18:572–574.
2.
GelinckLBS and BurgerDM: Switching from efavirenz to nevirapine. Clin Infect Dis, 2010; 51:365.
3.
LaureillardD, PrakN, FernandezM, NgethC, MoeungS, RielV, et al.: Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia. HIV Med, 2008; 9:514–518.
4.
Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access. Recommendations for a Public Health Approach. 2010 revision. World Health Organization, Geneva, 2010.
5.
World Health Organization: Antiretroviral therapy for HIV infection in adults and adolescents. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf. Accessed February10, 2012.
6.
PhanuphakP, LeechawengwongM, SiraprapasiriT, ChantratrtaW, TechasathitW, TeerakulA, et al.: National Guideline on HIV/AIDS Diagnosis and Treatment, Thailand, 2010. http://dpc10.ddc.moph.go.th/km55/aids/ThaiGuidelineonHIVdiagnosisandtreatment2010.pdf. Accessed March10, 2012.
AntónP, SorianoV, Jiménez-NácherI, Rodriguez-RosadoR, DonaMC, BarreiroPM, et al.: Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. AIDS, 1999; 13:524–525.
9.
MulengaV, CookA, WalkerAS, KabambaD, ChijokaC, FerrierA, et al.: Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination “baby pills” in Zambia: A randomized controlled trial. Clin Infect Dis, 2010; 51:1081–1089.
10.
AnanworanichJ, MoorZ, SiangphoeU, ChanJ, CardielloP, DuncombeC, et al.: Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS, 2005; 19:185–192.
11.
van LethF, AndrewsS, GrinsztejnB, WilkinsE, LazanasMK, LangeJM, et al.: The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS, 2005; 19:463–471.
12.
Bersoff-MatchaSJ, MillerWC, AbergJA, van Der HorstC, HamrickHJJr, PowderlyWG, et al.: Sex differences in nevirapine rash. Infect Dis, 2001; 32:124–129.
13.
MazhudeC, JonesS, MuradS, TaylorC, and EasterbrookP: Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS, 2002; 16:1566–1568.
14.
ParientiJJ, MassariV, ReyD, PoubeauP, VerdonR, and the SIROCCO study team: Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: A randomized, controlled study. Clin Infect Dis, 2007; 45:263–266.
15.
BangsbergDR, RaglandK, MonkA, and DeeksSG: A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+homeless and marginally housed people. AIDS, 2010; 24:2835–2840.
